Rubius Therapeutics

Rubius Therapeutics, Inc. was a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. It was founded in 2013 to translate discoveries in genetic engineering and cell culture into a new class of medicines based on red blood cells, which the company called Red Cell Therapeutics (RCT). The scientific foundation came from the work of Professors Harvey Lodish and Hidde Ploegh at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, combined with the venture-creation expertise of Flagship Pioneering's VentureLabs. The company's core idea was to engineer red blood cells — the body's most abundant cell type — to carry therapeutic payloads, thereby creating off-the-shelf cellular therapies that could avoid some of the manufacturing and immune-compatibility challenges of other cell therapy approaches. Rubius Therapeutics focused its development programs on three broad areas: cancer, enzyme replacement therapies, and autoimmune diseases. Its pipeline included RCT product candidates for rare diseases, such as RTX-134 for the treatment of phenylketonuria (PKU), followed by RTX-Uricase for chronic refractory gout and RTX-CBS for symptomatic homocystinuria. The company went public on the NASDAQ stock exchange on 18 July 2018, issuing 9,530,000 shares in its initial public offering. At its peak, Rubius was one of the larger cell-therapy-focused biotechs to emerge from the Flagship Pioneering ecosystem. Despite its scientific ambition and substantial capital raised, Rubius Therapeutics struggled to advance its RCT platform through clinical development. The company eventually wound down its operations and delisted from NASDAQ, and its intellectual property and remaining assets were sold off. The rubiustx.com domain later came under unrelated ownership and, as of 2025, hosts content about online casinos in Australia — a use entirely disconnected from the original biopharmaceutical business. The Rubius Therapeutics story is often cited as an example of the high risk and capital intensity of novel cell-therapy platforms, even when backed by prominent scientific founders and blue-chip venture investors.

Rubius Therapeutics was founded in 2013 in Cambridge, Massachusetts, based on discoveries by Professors Harvey Lodish and Hidde Ploegh at the Whitehead Institute for Biomedical Research at MIT, together with research and insights from Flagship Pioneering's VentureLabs. The company was built around a novel scientific premise: that red blood cells could be engineered ex vivo and reintroduced into the body as a platform for delivering therapeutic proteins, thereby creating a new class of cellular medicines called Red Cell Therapeutics (RCT). This approach aimed to combine the advantages of cell therapy with the scalability and safety profile of a universally transfusable cell type. The company's therapeutic focus areas were cancer, enzyme replacement, and autoimmune diseases. Its pipeline included RCT product candidates for rare diseases, notably RTX-134 for phenylketonuria (PKU), followed by RTX-Uricase for chronic refractory gout and RTX-CBS for symptomatic homocystinuria. These programs were designed to address serious metabolic and enzymatic disorders where existing treatments were burdensome or inadequate. Rubius Therapeutics went public on the NASDAQ stock exchange on 18 July 2018, issuing 9,530,000 shares in its initial public offering. The IPO was one of the larger biotech listings of that period and provided the company with substantial capital to advance its RCT platform. However, like many novel cell-therapy companies, Rubius faced significant scientific, manufacturing, and clinical challenges. The complexity of engineering red blood cells at scale and demonstrating clear clinical benefit proved difficult, and the company's programs did not achieve the milestones needed to sustain its operations. Ultimately, Rubius Therapeutics wound down its business, delisted from NASDAQ, and sold off its assets. The rubiustx.com domain, once the company's corporate home, later came under unrelated ownership. By 2025, the site hosted content about online casinos in Australia, a use completely disconnected from the original biopharmaceutical enterprise. The trajectory of Rubius Therapeutics illustrates both the promise and the peril of platform-based drug development, where a compelling scientific concept must still overcome formidable translational and commercial hurdles.

• 2018

  Initial public offering on NASDAQ on 18 July 2018, issuing 9,530,000 shares.

• 2013

  Rubius Therapeutics founded in Cambridge, Massachusetts, based on discoveries at MIT's Whitehead Institute and Flagship Pioneering's VentureLabs.

• Company winds down operations, delists from NASDAQ, and sells off assets.

Clinical-stage biopharmaceutical company developing a novel red-blood-cell-based cell therapy platform for cancer, enzyme deficiencies, and autoimmune diseases.

• Red Cell Therapeutics (RCT) platform

  A red-blood-cell-based cell therapy platform for applications in cancer, enzyme replacement, and autoimmune diseases.

• RTX-134

  Product candidate for the treatment of phenylketonuria (PKU).

• RTX-Uricase

  Product candidate for chronic refractory gout.

• RTX-CBS

  Product candidate for symptomatic homocystinuria.

1. 1Rubius Therapeutics (Wikipedia DE)de.wikipedia.org
2. 2Rubius Therapeutics (Wikidata)wikidata.org
3. 3RubiusTX official websiterubiustx.com
4. 4About Us – RubiusTXrubiustx.com